U
GLMD icon

UBS’s Galmed Pharmaceuticals GLMD Stock Holding History

UBS’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-11
Closed -$23K – 10557
2014
Q1 		$23K Buy
+11
New +$25.8K ﹤0.01% 7897

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

UBS's GLMD Position: Q2 2014 in Review

UBS sold out of Galmed Pharmaceuticals (GLMD) in Q2 2014, closing a stake of 11 shares — an estimated $23K sold.

UBS first reported a position in GLMD in Q1 2014 and held it in 1 quarter. The position peaked at $23K in Q1 2014. 20 funds tracked by Wall St. Rank hold GLMD as of Q2 2014.

  • UBS reported no remaining Galmed Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • UBS sold 11 Galmed Pharmaceuticals shares in Q2 2014, an estimated $23K.
  • UBS first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • UBS's Galmed Pharmaceuticals position peaked at $23K in Q1 2014.
  • 20 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.